Cardinal Health, Inc.

Cardinal Health trades at a P/E of 29.55—substantially elevated for a wholesale drug distributor typically valued for steady cash generation rather than growth. With an RSI of 41.2, the stock sits in neutral territory without oversold pressure, suggesting recent selling has stabilized but without capitulation. The 2.89% short float is negligible, ruling out meaningful squeeze dynamics. Trading below its 52-week high despite a rich multiple hints at headwinds: either margin compression from competitive pricing pressures in pharmaceutical distribution or concerns about regulatory/legislative threats to drug pricing. For a defensive sector name to command this valuation multiple, the market is pricing in either exceptional earnings growth or perceiving the stock as a relative safe haven—neither narrative appears obviously compelling given the structural pressures facing wholesalers.